RT Journal Article
SR Electronic
T1 Fertility care among people with primary ciliary dyskinesia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.04.23292228
DO 10.1101/2023.07.04.23292228
A1 Schreck, Leonie D
A1 Goutaki, Myrofora
A1 Jörger, Philippa
A1 Dexter, Katie
A1 Manion, Michele
A1 Christin-Maitre, Sophie
A1 Maitre, Bernard
A1 COVID-PCD patient advisory group
A1 Kuehni, Claudia E
A1 Pedersen, Eva SL
YR 2023
UL http://medrxiv.org/content/early/2023/07/05/2023.07.04.23292228.abstract
AB Introduction Fertility care is important for people living with primary ciliary dyskinesia (PCD) who are at increased risk of fertility problems. We investigated fertility care in an international participatory study.Methods Participants of the COVID-PCD study completed an online questionnaire addressing fertility issues. We used logistic regression to study factors associated with fertility specialist visits.Results Among 384 respondents (response rate 53%), 266 were adults [median age 44 years, interquartile range (IQR) 33–54), 68% female], 16 adolescents, and 102 parents of children with PCD. Half adult participants (128; 48%) received care from fertility specialists at a median age of 30 years (IQR 27–33)—a median of 10 years after PCD diagnosis. Fertility specialist visits were reported more often by adults with pregnancy attempts [odds ratio (OR) 9.1, 95% confidence interval (CI) 3.8–23.6] and among people who reported fertility as important for them (OR 5.9, 95% CI 2.6–14.6) and less often by females (OR 0.4, 95% CI 0.2–0.8). Only 56% of participants who talked with healthcare professionals about fertility were satisfied with information they received. They expressed needs for more comprehensive fertility information and reported dissatisfaction with physician knowledge about PCD and fertility.Conclusion People with PCD are inconsistently referred to fertility specialists. We recommend care from fertility specialists become standard in routine PCD care, and that PCD physicians provide initial fertility information either at diagnosis or no later than transition to adult care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOur research was funded by the Swiss National Science Foundation, Switzerland (SNSF 320030B_192804/1), the Swiss Lung Association, Switzerland (2021-08_Pedersen), and we also received support from the PCD Foundation, United States; the Verein Kartagener Syndrom und Primaere Ciliaere Dyskinesie, Germany; the PCD Support UK; and PCD Australia, Australia. M. Goutaki receives funding from the Swiss National Science Foundation (PZ00P3_185923). Study authors participate in the BEAT-PCD Clinical Research Collaboration supported by the European Respiratory Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Bern Cantonal Ethics Committee (Kantonale Ethikkomission Bern) approved our study (Study ID: 2020-00830). Participants provide their informed consent to participate in the study at registration. Participation is anonymous. Participants can withdraw consent to participate at any time by contacting the study team.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors